ClinicalTrials.gg
Not yet recruitingNCT07333170P versicolorUpdated Jan 12, 2026

Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor.

A Phase 4 interventional study of Luliconazole Cream 1% and Topical ketoconazole 2% cream in Pityriasis Versicolor, sponsored by PAEC General Hospital, Islamabad. Not yet recruiting. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by PAEC General Hospital, Islamabad · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Pityriasis versicolor is a common superficial fungal infection caused by Malassezia species, characterized by hypo- or hyper-pigmented scaly patches on the skin. Topical antifungal agents are the mainstay of treatment. Ketoconazole has been widely used; however, newer agents such as luliconazole may offer improved efficacy and shorter treatment duration. This randomized controlled study aims to compare the efficacy and safety of topical luliconazole versus topical ketoconazole in patients with pityriasis versicolor. Treatment response will be assessed clinically and mycologically to determine comparative outcomes.

Read the detailed description

Pityriasis versicolor is a superficial fungal infection caused by Malassezia species and is commonly treated with topical antifungal agents. Ketoconazole is a conventional treatment, while luliconazole is a newer topical antifungal with potent activity against fungal organisms. This randomized controlled trial is designed to compare the clinical and mycological efficacy, safety, and tolerability of topical luliconazole versus topical ketoconazole in patients diagnosed with pityriasis versicolor. Eligible participants will be randomly allocated into two treatment groups and followed for treatment response and adverse effects. The findings of this study may help determine a more effective topical treatment option for pityriasis versicolor.

02

Conditions studied

  • Pityriasis Versicolor

Keywords

  • P versicolor
03

In context

Lead sponsor

PAEC General Hospital, Islamabad is the lead sponsor of 9 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients diagnosed with pityriasis versicolor.

Exclusion criteria

Exclusion Criteria:

  • patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    Topical Luliconazole 1% cream

    Participants will receive topical luliconazole 1% cream applied once daily to affected areas for the treatment of pityriasis versicolor.

    Drug: Luliconazole Cream 1%

  • Experimental
    Topical ketoconazole 2% cream

    Participants will receive topical ketoconazole 2% cream applied twice daily to affected areas for the treatment of pityriasis versicolor.

    Drug: Topical ketoconazole 2% cream

Interventions

  • DrugLuliconazoleStudies of LuliconazoleLuliconazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ketoconazole is relatively hydrophilic with limited skin retention, whereas luliconazole is highly lipophilic, resulting in superior stratum corneum penetration, higher keratin binding, and prolonged antifungal activity.

  • DrugKetoconazoleStudies of KetoconazoleKetoconazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ketoconazole is relatively hydrophilic with limited skin retention, whereas luliconazole is highly lipophilic, resulting in superior stratum corneum penetration, higher keratin binding, and prolonged antifungal activity.

06

What researchers measure

Primary outcomes

  1. Clinical and mycological cure rate in pityriasis versicolor.

    Proportion of participants achieving both clinical and mycological cure.

    Time frame: 4 weeks

  2. Clinical and mycological cure

    Proportion of participants achieving both clinical and mycological cure

    Time frame: 4 weeks after completion of treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

Individual participant data

Plan to share: No — Individual participant data from this study will not be shared, as it is a small, single center based study. aggregate forms will be used to analyze the results. To ensure patients confidentiality data sharing is limited. Beyond the stated study object the dataset will not be used for any secondary purpose.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Jul 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jan 12, 2026
StartEst.
Feb 2026
Primary completionEst.
Jul 2026
CompletionEst.
Nov 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07333170
Lead sponsor
PAEC General Hospital, Islamabad
Collaborators
PAEC general hospital
Responsible party
Sana Rafique (Post graduate trainee, PAEC General Hospital, Islamabad) — Principal investigator
First posted
Jan 12, 2026
Start date
Feb 2026 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jan 12, 2026

Study contacts

Sana Rafique, MBBS
Contact
sanafmdc@gmail.com
+923355956563

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Luliconazole · Ketoconazole

Start the discussion